Giannini E H, Barron K S, Spencer C H, Person D A, Baum J, Bernstein B H, Kredich D W, Jacobs J C, Zemel L S, Gibbas D
Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, OH 45229.
J Rheumatol. 1991 Aug;18(8):1240-2.
Eighty-eight children with juvenile rheumatoid arthritis (JRA) who completed a double blind, randomized placebo controlled trial of oral gold were entered into an open label extension phase during which they received auranofin (AF) at a dosage of 0.15-0.2 mg/kg/day (9 mg/day maximum). Eleven (12.5%) patients completed 5 years of AF therapy; 77 (87.5%) did not. Fifteen (17%) of the 88 were in disease remission at the final visit. Mean duration of therapy for those who discontinued was 646 days. Parental/patient decision and insufficient therapeutic effect were the 2 most frequent reasons for early termination, followed by adverse effects. Though relatively well tolerated, AF provides adequate longterm management for only a small percentage of patients with JRA.
88名完成口服金制剂双盲随机安慰剂对照试验的幼年类风湿性关节炎（JRA）患儿进入开放标签延长期，在此期间他们接受金诺芬（AF）治疗，剂量为0.15 - 0.2毫克/千克/天（最大9毫克/天）。11名（12.5%）患者完成了5年的AF治疗；77名（87.5%）未完成。88名患者中有15名（17%）在最后一次随访时疾病缓解。停药患者的平均治疗持续时间为646天。家长/患者的决定和治疗效果不佳是早期终止治疗的两个最常见原因，其次是不良反应。尽管AF耐受性相对较好，但仅能为一小部分JRA患者提供充分的长期治疗。
